Cargando…

Benefit, Risk and Cost in Oral Anticoagulation for Stroke Prevention: Is It the Third Factor?

Detalles Bibliográficos
Autor principal:	Choi, Jong-Il
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393324/ https://www.ncbi.nlm.nih.gov/pubmed/30808075 http://dx.doi.org/10.4070/kcj.2019.0007

Ejemplares similares

Stroke prevention within primary care: management of atrial fibrillation using oral anticoagulation
por: Lotufo, Paulo Andrade
Publicado: (2018)

Newer Oral Anticoagulants: Stroke Prevention and Pitfalls
por: Patel, Anand, et al.
Publicado: (2016)

Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants
por: Luger, Sebastian, et al.
Publicado: (2015)

Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients
por: Scanavacca, Maurício, et al.
Publicado: (2016)

Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation
por: Mani, Helen, et al.
Publicado: (2015)

Recent Management Option for Hemorrhagic Stroke during Direct Oral Anticoagulant Therapy
por: Fujimura, Miki
Publicado: (2023)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention
por: Habert, Jeffrey Steven
Publicado: (2016)

Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis
por: Mendoza-Sanchez, Jose, et al.
Publicado: (2018)

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Oral anticoagulation in elderly patients as secondary prevention of cardioembolic strokes
por: Benavente, Lorena, et al.
Publicado: (2010)

Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?
por: Kuo, Ling, et al.
Publicado: (2017)

The Primary Goal of Anticoagulation in Atrial Fibrillation to Prevent Stroke and Not to Offer the Apparently Cheapest Treatment
por: Diener, Hans-Christoph
Publicado: (2014)

Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin
por: Ansell, Jack
Publicado: (2017)

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
por: López-López, José A, et al.
Publicado: (2017)

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Publicado: (2018)

In Search of Safe and Effective Oral Anticoagulation
por: Curtiss, Frederic R.
Publicado: (2005)

Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
por: Atterman, Adriano, et al.
Publicado: (2021)

Preventing stroke in atrial fibrillation patients – clinical utility of oral anticoagulants
por: Jhawar, Manish B, et al.
Publicado: (2012)

Direct oral anticoagulant failure in stroke/transient ischaemic attack: neurologic and pharmacokinetic considerations
por: Rose, David Z, et al.
Publicado: (2020)

Acute Stroke Treatment in Patients Receiving Direct Oral Anticoagulants: Is it Time to Review the Guidelines?
por: Ojha, Pawan K., et al.
Publicado: (2023)

Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
por: Verhoef, Talitha I., et al.
Publicado: (2014)

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention
por: Paciaroni, Maurizio, et al.
Publicado: (2021)

Patient Perspectives on Factors Affecting Direct Oral Anticoagulant Use for Stroke Prevention in Atrial Fibrillation
por: Medlinskiene, Kristina, et al.
Publicado: (2021)

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)
por: Jung, Moonki, et al.
Publicado: (2023)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2021)

Ischemic Stroke Risk Factors in Patients with Atrial Fibrillation Treated with New Oral Anticoagulants
por: Wańkowicz, Paweł, et al.
Publicado: (2021)

Response to editorial comment ‘Direct oral anticoagulant failure in TIA/stroke: neurologic and pharmacokinetic considerations’
por: Huynh, Ronald, et al.
Publicado: (2020)

Benefits and risks of sugammadex
por: Park, Jong-Yeon
Publicado: (2015)

Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
por: Kim, Jong S.
Publicado: (2019)

Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information Analysis
por: Thom, Howard H. Z., et al.
Publicado: (2019)

Intra-procedural anticoagulation protocols for left-sided cardiac ablations: Striking a balance between risk and benefit
por: Siontis, Konstantinos C.
Publicado: (2016)

Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?
por: Smit, M. D., et al.
Publicado: (2011)

Unconventional, Yet Important, Risk Factors for Stroke
por: Kim, Jong S.
Publicado: (2018)

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
por: Chang, Ting-Yung, et al.
Publicado: (2018)

Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials
por: Carbone, Andreina, et al.
Publicado: (2023)

Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study
por: Azahar, Siti Norain, et al.
Publicado: (2022)

A ‘Gender Paradox’ of Female as a Stroke Risk in Atrial Fibrillation: Do Women Live Longer Than Men?
por: Jeong, Joo Hee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p3bag3apl2isb4rg65ng2jbalu